AstraZeneca has reportedly rejected a reported $106 billion buyout offer made by US peer Pfizer last Friday, claiming the bid “substantially” undervalued the company.
According to reports, Pfizer submitted its bid and UK-based AstraZeneca rejected it all in the same day. Should the companies eventually agree on a price tag, such a merger would create the world’s largest pharmaceuticals company, reports say.
Industry experts have suggested that Pfizer could take its offer straight to AstraZeneca shareholders in search of striking a deal. The firm is said to prefer an agreed-upon deal, however, as hostile acquisitions take longer to complete.
AstraZeneca’s dismissal of the offer was not the first such rejection; an earlier offer by Pfizer was also rejected.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Business Secretary Calls for More Agile Competition Regulator
Feb 13, 2025 by
CPI
Germany’s Antitrust Regulator Raises Concerns Over Apple’s App Tracking Policies
Feb 13, 2025 by
CPI
$60 Billion Nissan-Honda Merger Falls Apart
Feb 13, 2025 by
CPI
DOJ Moves to End Protections for Three Regulatory Agencies
Feb 13, 2025 by
CPI
Meta to Allow Rivals to List Ads on Facebook Marketplace Following EU Fine
Feb 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon